Core Insights - Clearside Biomedical is showcasing its SCS Microinjector platform and CLS-AX program at the 25th EURETINA Congress, highlighting its potential for treating multiple retinal diseases [1][3] Group 1: SCS Microinjector Platform - The SCS delivery platform is designed for targeted treatment of retinal diseases such as wet AMD, diabetic retinopathy, and ocular cancer [2] - The SCS Microinjector allows for the delivery of various drug candidates into the suprachoroidal space, aiming to improve efficacy and reduce toxic effects on non-diseased cells [8][9] Group 2: CLS-AX Program - CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection, which may offer advantages over existing retinal therapies by achieving pan-VEGF blockade [6][7] - The program includes a Phase 3 trial for wet AMD and a streamlined Phase 2 trial for non-proliferative diabetic retinopathy [3] Group 3: Upcoming Presentations - Dr. Sobha Sivaprasad will present Phase 2b results from the ODYSSEY trial and updates on the Phase 3 program for neovascular age-related macular degeneration [4] - Victor Chong will discuss the evolution of suprachoroidal drug delivery and participate in a panel at the Ophthalmology Futures Retina Forum [5]

Core Insights - Clearside Biomedical, Inc. is exploring a range of strategic alternatives to enhance its SCS platform and drug development pipeline, aiming to maximize stockholder value [1][2][3] - The company has retained Piper Sandler to assist in the strategic evaluation process, considering options such as asset sales, licensing, collaborations, and mergers [1][2] - Clearside's SCS Microinjector is a validated delivery platform for therapies targeting serious retinal diseases, with five commercial and late-stage development collaborations [1][4][10] Company Highlights - The SCS Microinjector enables a non-surgical, repeatable procedure for targeted delivery of therapies to the macula, retina, and choroid, potentially preserving and improving vision in patients with sight-threatening eye diseases [4][10] - Clearside's lead program, CLS-AX, is in development for the treatment of wet age-related macular degeneration (AMD) and has shown positive Phase 2b clinical data [2][8][10] - The company has successfully navigated the FDA regulatory pathway for its first product, XIPERE, which is approved for suprachoroidal use [8][10] Internal Pipeline - CLS-AX is a proprietary axitinib injectable suspension being developed for wet AMD, with a Phase 3 program planned to maximize its commercial potential [8][10] - The company is also evaluating small molecules for treating geographic atrophy (GA) and diabetic macular edema (DME), addressing high unmet medical needs in retinal diseases [8][10] External Collaborations - Clearside has established partnerships with various companies utilizing its SCS injection platform for other ophthalmic therapeutic innovations, including gene therapies and anti-tumor agents [10][13]

Core Insights - Clearside Biomedical is advancing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS) injection platform, which will be highlighted at the upcoming Clinical Trials at the Summit (CTS) Meeting [1][2] Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on improving patient outcomes by utilizing its SCS injection platform for targeted delivery of therapies to treat sight-threatening eye diseases [7] - The company’s lead product, CLS-AX (axitinib injectable suspension), is in development for neovascular age-related macular degeneration (wet AMD) and is preparing for a Phase 3 program [7] Technology and Innovation - The SCS Microinjector is a patented device that allows for in-office, repeatable, non-surgical procedures to deliver a variety of therapies directly to the macula, retina, or choroid [5][7] - CLS-AX is designed as a longer-acting therapy that achieves pan-VEGF blockade, potentially offering advantages over existing anti-VEGF therapies by targeting different levels of the angiogenesis cascade [4][5] Clinical Development - The company is showcasing multiple presentations related to its SCS delivery platform and its development partners at the CTS Meeting, including updates on CLS-AX for neovascular AMD and ABBV-RGX-314 for diabetic retinopathy [3][4] - Early clinical trials for CLS-AX have shown it to be well tolerated with a positive safety profile, indicating its potential for prolonged duration and targeted delivery [4]

Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) to improve patient outcomes [3] - The company utilizes a patented SCS Microinjector for an in-office, repeatable, non-surgical procedure aimed at targeted delivery of therapies to the macula, retina, or choroid [3] - Clearside is developing a pipeline of small molecule product candidates for administration via its SCS Microinjector, with its lead program, CLS-AX, in development for treating neovascular age-related macular degeneration (wet AMD) [3] Product Development - The company is planning a Phase 3 program for its lead product, CLS-AX (axitinib injectable suspension) [3] - Clearside is also evaluating various small molecules for potential long-acting treatment of geographic atrophy (GA) [3] - The first product developed by Clearside, XIPERE (triamcinolone acetonide injectable suspension), has been approved for suprachoroidal use and is available in the U.S. through a commercial partner [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025, at 9:00 a.m. ET [1] - A live and archived webcast of the event will be accessible on the Clearside website under the Investors section, with the archive available for three months [2]

Core Insights - Clearside Biomedical has successfully completed an End-of-Phase 2 meeting with the FDA, leading to alignment on the Phase 3 program design for CLS-AX in wet AMD [1][5] - The company aims for a flexible three-to-six-month dosing label for CLS-AX, which is expected to be commercially attractive if approved [2][5] - Significant progress has been made by Clearside's partners in advancing their programs, including approvals and ongoing clinical trials [2][5] Recent Highlights - BioCryst Pharmaceuticals has received authorization to initiate its first clinical trial in Australia for avoralstat, targeting diabetic macular edema [5] - Arctic Vision's NDA for ARCATUS has been accepted for review in China, with approvals already granted in Australia and Singapore [5] - Over 15 presentations on suprachoroidal drug delivery were made at major ophthalmic medical meetings this year, showcasing advancements in retinal disease treatments [1][5] Financial Results - License and other revenue for Q1 2025 was $2.3 million, a significant increase from $0.2 million in Q1 2024, primarily due to license fees from partners [8][11] - R&D expenses decreased to $4.5 million in Q1 2025 from $5.6 million in Q1 2024, attributed to lower clinical trial costs [8][11] - The net loss for Q1 2025 was $8.2 million, or $0.11 per share, compared to a net loss of $11.8 million, or $0.17 per share, in Q1 2024 [8][11] Company Overview - Clearside Biomedical focuses on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, aiming to improve patient outcomes [6] - The company's lead program, CLS-AX, is in development for the treatment of wet AMD, with plans for a Phase 3 program underway [6] - Clearside has developed its first product, XIPERE, which is commercially available in the U.S. through a partner [6][9]

Core Insights - Clearside Biomedical, Inc. is advancing the treatment of multiple macular diseases through its suprachoroidal drug delivery platform, highlighted by positive clinical data for its lead program, CLS-AX [1][2] Presentation Highlights - Six presentations at the ARVO 2025 Meeting showcased the efficacy and safety of CLS-AX, particularly its ability to maintain stable best corrected visual acuity (BCVA) while reducing injection frequency in patients with neovascular age-related macular degeneration (nAMD) [1][5] - The Phase 2b ODYSSEY trial demonstrated that CLS-AX offers durability and therapeutic potential, achieving its primary outcome [5] - The suprachoroidal delivery method is positioned as a transformative approach for treating retinal diseases, with Clearside recognized as a leader in this field [2][5] Technological Innovations - Clearside has developed a machine learning algorithm for imaging the suprachoroidal space (SCS) post-drug delivery, enhancing patient data evaluation [5] - The SCS Microinjector, designed for targeted drug delivery, has completed over 15,000 injections, establishing a clinically validated training program [5][9] Product Development - CLS-AX is a proprietary suspension of axitinib, a tyrosine kinase inhibitor, which has shown a positive safety profile in clinical trials and aims to provide prolonged and targeted delivery for retinal diseases [8][10] - The company is also planning a Phase 3 trial for CLS-AX and evaluating other small molecules for potential long-acting treatments [10]

Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [3] - The company utilizes a patented SCS Microinjector for targeted and compartmentalized delivery of therapies, aiming to improve patient outcomes in sight-threatening eye diseases [3] - Clearside's lead program, CLS-AX (axitinib injectable suspension), is in development for treating neovascular age-related macular degeneration (wet AMD), with planning for a Phase 3 program underway [3] Product Development - Clearside has developed its first product, XIPERE (triamcinolone acetonide injectable suspension), which is approved for suprachoroidal use and available in the U.S. through a commercial partner [3] - The company is also evaluating various small molecules for potential long-acting treatment of geographic atrophy (GA) [3] - Clearside strategically partners its SCS injection platform with other companies utilizing ophthalmic therapeutic innovations [3] Financial Information - The company will report its first quarter 2025 financial results on May 14, 2025, after the close of financial markets [1] - There will be no conference call hosted for this quarter [1]

Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [3] - The company utilizes a patented SCS Microinjector for an in-office, repeatable, non-surgical procedure aimed at delivering therapies to the macula, retina, or choroid [3] - Clearside is developing a pipeline of small molecule product candidates for administration via its SCS Microinjector, with its lead program, CLS-AX, targeting neovascular age-related macular degeneration (wet AMD) [3] Product Development - The company is planning a Phase 3 program for its lead product, CLS-AX (axitinib injectable suspension) [3] - Clearside is also evaluating various small molecules for potential long-acting treatment of geographic atrophy (GA) [3] - The first product developed by Clearside, XIPERE (triamcinolone acetonide injectable suspension), has been approved for suprachoroidal use and is available in the U.S. through a commercial partner [3] Upcoming Events - Management will participate in a fireside chat at the Citizens Life Sciences Conference on May 7, 2025, at 1:00 p.m. ET [1] - A live and archived webcast of the event will be accessible on the Clearside website under the Investors section, with the archive available for three months [2]